Literature DB >> 22634372

Brain transcriptomic profiling in idiopathic and LRRK2-associated Parkinson's disease.

Teresa Botta-Orfila1, Alex Sànchez-Pla, Manel Fernández, Francesc Carmona, Mario Ezquerra, Eduard Tolosa.   

Abstract

LRRK2 mutations are the most common genetic cause of Parkinson's disease (PD). We performed a whole-genome RNA profiling of locus coeruleus post-mortem tissue, a histopathologically affected brain tissue in PD, from idiopathic PD (IPD) and LRRK2-associated PD patients. The differentially expressed genes found in IPD and LRRK2-associated PD are involved in the gene ontology terms of synaptic transmission and neuron projection. In addition, differentially expressed genes in the IPD group are associated with immune system related pathways. Specifically, the study performed highlights the presence of differential expression of genes located in the chromosome 6p21.3 belonging to the class II HLA. Our findings support the hypothesis of a potential role of neuroinflammation and the involvement of the HLA genetic area in IPD pathogenesis. Future studies are necessary to shed light on the relation of immune system related pathways in the etiopathogenesis of PD.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22634372     DOI: 10.1016/j.brainres.2012.05.036

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  9 in total

1.  Gene expression profiling analysis of locus coeruleus in idiopathic Parkinson's disease by bioinformatics.

Authors:  Shuqin Cui; Hanwen Sun; Xiangling Gu; E Lv; Yancong Zhang; Pingxuan Dong; Chunhua Fu; Chao Zhu
Journal:  Neurol Sci       Date:  2014-08-13       Impact factor: 3.307

Review 2.  Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.

Authors:  Soumya Ray; Min Liu
Journal:  Future Med Chem       Date:  2012-09       Impact factor: 3.808

Review 3.  Long Road to Ruin: Noradrenergic Dysfunction in Neurodegenerative Disease.

Authors:  David Weinshenker
Journal:  Trends Neurosci       Date:  2018-02-20       Impact factor: 13.837

Review 4.  The role of innate and adaptive immunity in Parkinson's disease.

Authors:  George T Kannarkat; Jeremy M Boss; Malú G Tansey
Journal:  J Parkinsons Dis       Date:  2013       Impact factor: 5.568

5.  Dopamine neuron-specific LRRK2 G2019S effects on gene expression revealed by translatome profiling.

Authors:  Judit Pallos; Sophia Jeng; Shannon McWeeney; Ian Martin
Journal:  Neurobiol Dis       Date:  2021-05-11       Impact factor: 5.996

6.  Evidence for Immune Response, Axonal Dysfunction and Reduced Endocytosis in the Substantia Nigra in Early Stage Parkinson's Disease.

Authors:  Anke A Dijkstra; Angela Ingrassia; Renee X de Menezes; Ronald E van Kesteren; Annemieke J M Rozemuller; Peter Heutink; Wilma D J van de Berg
Journal:  PLoS One       Date:  2015-06-18       Impact factor: 3.240

7.  Next-generation profiling to identify the molecular etiology of Parkinson dementia.

Authors:  Adrienne Henderson-Smith; Jason J Corneveaux; Matthew De Both; Lori Cuyugan; Winnie S Liang; Matthew Huentelman; Charles Adler; Erika Driver-Dunckley; Thomas G Beach; Travis L Dunckley
Journal:  Neurol Genet       Date:  2016-05-24

8.  Comparative Transcriptome Analysis in Monocyte-Derived Macrophages of Asymptomatic GBA Mutation Carriers and Patients with GBA-Associated Parkinson's Disease.

Authors:  Tatiana Usenko; Anastasia Bezrukova; Katerina Basharova; Alexandra Panteleeva; Mikhail Nikolaev; Alena Kopytova; Irina Miliukhina; Anton Emelyanov; Ekaterina Zakharova; Sofya Pchelina
Journal:  Genes (Basel)       Date:  2021-09-29       Impact factor: 4.096

9.  Proteome profiling of cerebrospinal fluid reveals biomarker candidates for Parkinson's disease.

Authors:  Ozge Karayel; Sebastian Virreira Winter; Shalini Padmanabhan; Yuliya I Kuras; Duc Tung Vu; Idil Tuncali; Kalpana Merchant; Anne-Marie Wills; Clemens R Scherzer; Matthias Mann
Journal:  Cell Rep Med       Date:  2022-06-21
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.